ALZCHEM GROUP AG (ACT.DE) Stock Fundamental Analysis

FRA:ACT • DE000A2YNT30

144.2 EUR
0 (0%)
Last: Feb 13, 2026, 05:29 PM
Fundamental Rating

7

Overall ACT gets a fundamental rating of 7 out of 10. We evaluated ACT against 73 industry peers in the Chemicals industry. ACT has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. ACT is not valued too expensively and it also shows a decent growth rate. These ratings could make ACT a good candidate for quality investing.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year ACT was profitable.
  • In the past year ACT had a positive cash flow from operations.
  • Each year in the past 5 years ACT has been profitable.
  • Of the past 5 years ACT 4 years had a positive operating cash flow.
ACT.DE Yearly Net Income VS EBIT VS OCF VS FCFACT.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M 100M

1.2 Ratios

  • The Return On Assets of ACT (10.49%) is better than 94.52% of its industry peers.
  • ACT has a Return On Equity of 26.47%. This is amongst the best in the industry. ACT outperforms 94.52% of its industry peers.
  • ACT has a Return On Invested Capital of 13.45%. This is amongst the best in the industry. ACT outperforms 93.15% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for ACT is above the industry average of 7.31%.
  • The 3 year average ROIC (12.06%) for ACT is below the current ROIC(13.45%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 10.49%
ROE 26.47%
ROIC 13.45%
ROA(3y)8.81%
ROA(5y)7.86%
ROE(3y)22.87%
ROE(5y)25.91%
ROIC(3y)12.06%
ROIC(5y)10.63%
ACT.DE Yearly ROA, ROE, ROICACT.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

  • ACT has a better Profit Margin (10.97%) than 83.56% of its industry peers.
  • ACT's Profit Margin has improved in the last couple of years.
  • The Operating Margin of ACT (15.93%) is better than 84.93% of its industry peers.
  • ACT's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 66.55%, ACT belongs to the top of the industry, outperforming 97.26% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ACT has remained more or less at the same level.
Industry RankSector Rank
OM 15.93%
PM (TTM) 10.97%
GM 66.55%
OM growth 3Y17.53%
OM growth 5Y12.4%
PM growth 3Y14.29%
PM growth 5Y15.31%
GM growth 3Y2.01%
GM growth 5Y1.44%
ACT.DE Yearly Profit, Operating, Gross MarginsACT.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

9

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ACT is creating value.
  • Compared to 1 year ago, ACT has less shares outstanding
  • Compared to 5 years ago, ACT has less shares outstanding
  • The debt/assets ratio for ACT has been reduced compared to a year ago.
ACT.DE Yearly Shares OutstandingACT.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ACT.DE Yearly Total Debt VS Total AssetsACT.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 4.86 indicates that ACT is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.86, ACT belongs to the top of the industry, outperforming 87.67% of the companies in the same industry.
  • ACT has a debt to FCF ratio of 1.32. This is a very positive value and a sign of high solvency as it would only need 1.32 years to pay back of all of its debts.
  • ACT has a Debt to FCF ratio of 1.32. This is amongst the best in the industry. ACT outperforms 93.15% of its industry peers.
  • ACT has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of ACT (0.16) is better than 71.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 1.32
Altman-Z 4.86
ROIC/WACC1.85
WACC7.28%
ACT.DE Yearly LT Debt VS Equity VS FCFACT.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • ACT has a Current Ratio of 2.87. This indicates that ACT is financially healthy and has no problem in meeting its short term obligations.
  • ACT has a Current ratio of 2.87. This is amongst the best in the industry. ACT outperforms 83.56% of its industry peers.
  • A Quick Ratio of 1.77 indicates that ACT should not have too much problems paying its short term obligations.
  • The Quick ratio of ACT (1.77) is better than 82.19% of its industry peers.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 1.77
ACT.DE Yearly Current Assets VS Current LiabilitesACT.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

6

3. Growth

3.1 Past

  • ACT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.12%, which is quite impressive.
  • The Earnings Per Share has been growing by 24.60% on average over the past years. This is a very strong growth
  • Looking at the last year, ACT shows a small growth in Revenue. The Revenue has grown by 1.05% in the last year.
  • The Revenue has been growing by 8.06% on average over the past years. This is quite good.
EPS 1Y (TTM)24.12%
EPS 3Y25.02%
EPS 5Y24.6%
EPS Q2Q%31.66%
Revenue 1Y (TTM)1.05%
Revenue growth 3Y9.49%
Revenue growth 5Y8.06%
Sales Q2Q%6.46%

3.2 Future

  • The Earnings Per Share is expected to grow by 20.26% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 6.02% on average over the next years.
EPS Next Y21.07%
EPS Next 2Y12.7%
EPS Next 3Y18.06%
EPS Next 5Y20.26%
Revenue Next Year2.51%
Revenue Next 2Y5.13%
Revenue Next 3Y8.61%
Revenue Next 5Y6.02%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ACT.DE Yearly Revenue VS EstimatesACT.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ACT.DE Yearly EPS VS EstimatesACT.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2 4 6 8 10

4

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 23.64, the valuation of ACT can be described as rather expensive.
  • ACT's Price/Earnings ratio is in line with the industry average.
  • ACT's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.67.
  • Based on the Price/Forward Earnings ratio of 22.29, the valuation of ACT can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ACT is on the same level as its industry peers.
  • When comparing the Price/Forward Earnings ratio of ACT to the average of the S&P500 Index (27.69), we can say ACT is valued inline with the index average.
Industry RankSector Rank
PE 23.64
Fwd PE 22.29
ACT.DE Price Earnings VS Forward Price EarningsACT.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ACT is on the same level as its industry peers.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ACT is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 41.96
EV/EBITDA 12.35
ACT.DE Per share dataACT.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • ACT's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of ACT may justify a higher PE ratio.
  • A more expensive valuation may be justified as ACT's earnings are expected to grow with 18.06% in the coming years.
PEG (NY)1.12
PEG (5Y)0.96
EPS Next 2Y12.7%
EPS Next 3Y18.06%

4

5. Dividend

5.1 Amount

  • ACT has a Yearly Dividend Yield of 1.22%.
  • Compared to an average industry Dividend Yield of 2.26, ACT has a dividend in line with its industry peers.
  • ACT's Dividend Yield is slightly below the S&P500 average, which is at 1.80.
Industry RankSector Rank
Dividend Yield 1.22%

5.2 History

  • The dividend of ACT has a limited annual growth rate of 6.00%.
Dividend Growth(5Y)6%
Div Incr Years5
Div Non Decr Years5
ACT.DE Yearly Dividends per shareACT.DE Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 0.5 1 1.5

5.3 Sustainability

  • ACT pays out 49.16% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • The dividend of ACT is growing, but earnings are growing more, so the dividend growth is sustainable.
DP49.16%
EPS Next 2Y12.7%
EPS Next 3Y18.06%
ACT.DE Yearly Income VS Free CF VS DividendACT.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M
ACT.DE Dividend Payout.ACT.DE Dividend Payout, showing the Payout Ratio.ACT.DE Dividend Payout.PayoutRetained Earnings

ALZCHEM GROUP AG

FRA:ACT (2/13/2026, 5:29:51 PM)

144.2

0 (0%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)10-30
Earnings (Next)02-27
Inst Owners40.91%
Inst Owner ChangeN/A
Ins Owners28%
Ins Owner ChangeN/A
Market Cap1.47B
Revenue(TTM)563.86M
Net Income(TTM)61.84M
Analysts86
Price Target180.48 (25.16%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.22%
Yearly Dividend1.2
Dividend Growth(5Y)6%
DP49.16%
Div Incr Years5
Div Non Decr Years5
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.6%
PT rev (3m)11.74%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.34%
EPS NY rev (3m)2.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.31%
Valuation
Industry RankSector Rank
PE 23.64
Fwd PE 22.29
P/S 2.6
P/FCF 41.96
P/OCF 10.08
P/B 6.28
P/tB 6.38
EV/EBITDA 12.35
EPS(TTM)6.1
EY4.23%
EPS(NY)6.47
Fwd EY4.49%
FCF(TTM)3.44
FCFY2.38%
OCF(TTM)14.3
OCFY9.92%
SpS55.39
BVpS22.95
TBVpS22.6
PEG (NY)1.12
PEG (5Y)0.96
Graham Number56.13
Profitability
Industry RankSector Rank
ROA 10.49%
ROE 26.47%
ROCE 18.66%
ROIC 13.45%
ROICexc 16.12%
ROICexgc 16.26%
OM 15.93%
PM (TTM) 10.97%
GM 66.55%
FCFM 6.21%
ROA(3y)8.81%
ROA(5y)7.86%
ROE(3y)22.87%
ROE(5y)25.91%
ROIC(3y)12.06%
ROIC(5y)10.63%
ROICexc(3y)13.35%
ROICexc(5y)11.55%
ROICexgc(3y)13.5%
ROICexgc(5y)11.66%
ROCE(3y)16.73%
ROCE(5y)14.74%
ROICexgc growth 3Y25.57%
ROICexgc growth 5Y18.04%
ROICexc growth 3Y25.41%
ROICexc growth 5Y17.9%
OM growth 3Y17.53%
OM growth 5Y12.4%
PM growth 3Y14.29%
PM growth 5Y15.31%
GM growth 3Y2.01%
GM growth 5Y1.44%
F-Score6
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 1.32
Debt/EBITDA 0.33
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 125.34%
Profit Quality 56.58%
Current Ratio 2.87
Quick Ratio 1.77
Altman-Z 4.86
F-Score6
WACC7.28%
ROIC/WACC1.85
Cap/Depr(3y)118.98%
Cap/Depr(5y)119.68%
Cap/Sales(3y)5.65%
Cap/Sales(5y)6.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.12%
EPS 3Y25.02%
EPS 5Y24.6%
EPS Q2Q%31.66%
EPS Next Y21.07%
EPS Next 2Y12.7%
EPS Next 3Y18.06%
EPS Next 5Y20.26%
Revenue 1Y (TTM)1.05%
Revenue growth 3Y9.49%
Revenue growth 5Y8.06%
Sales Q2Q%6.46%
Revenue Next Year2.51%
Revenue Next 2Y5.13%
Revenue Next 3Y8.61%
Revenue Next 5Y6.02%
EBIT growth 1Y16.7%
EBIT growth 3Y28.68%
EBIT growth 5Y21.47%
EBIT Next Year50.25%
EBIT Next 3Y28.31%
EBIT Next 5Y19.11%
FCF growth 1Y37.23%
FCF growth 3Y62.42%
FCF growth 5Y94.14%
OCF growth 1Y166.77%
OCF growth 3Y34.7%
OCF growth 5Y19.23%

ALZCHEM GROUP AG / ACT.DE FAQ

Can you provide the ChartMill fundamental rating for ALZCHEM GROUP AG?

ChartMill assigns a fundamental rating of 7 / 10 to ACT.DE.


What is the valuation status for ACT stock?

ChartMill assigns a valuation rating of 4 / 10 to ALZCHEM GROUP AG (ACT.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for ALZCHEM GROUP AG?

ALZCHEM GROUP AG (ACT.DE) has a profitability rating of 9 / 10.


Can you provide the financial health for ACT stock?

The financial health rating of ALZCHEM GROUP AG (ACT.DE) is 9 / 10.


What is the earnings growth outlook for ALZCHEM GROUP AG?

The Earnings per Share (EPS) of ALZCHEM GROUP AG (ACT.DE) is expected to grow by 21.07% in the next year.